InsidersTradesSigma
Total declarations
Companies
▲ Purchases (20 ops.)
▼ Sales (5 ops.)
Insider track record
OtherDisclosed buys
20
Disclosed sells
5
T+90 hit rate
27%
T+90 mean return
-12.2%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Casdin Partners Master Fund, L.P.. Insider active across 6 companies, notably Verve Therapeutics, Inc.. Aggregated, 41 disclosures have been logged. Breakdown: 20 buys · 5 sells. Total volume traded: €107.4m. Activity tracked since 26 July 2021. The latest transaction was disclosed on 19 May 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations41 total
300,000 shares@ US$22.650.50% mcap15.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:0
650,000 shares@ US$23.701.14% mcap34.4% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:2
250,000 shares@ US$23.700.44% mcap13.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:1
27,994 sharesCommon Stock, par value $.001 per shareSEC:0000919574-25-002362:0
4,820,959 shares@ US$1.0655.1% of flowCommon StockSEC:0000919574-25-001777:0
Ideal exit: 25 Nov 2025 (T+270)
250,000 shares@ US$2.1870.5% of flowCommon StockSEC:0000919574-24-005134:0
Ideal exit: 24 May 2025 (T+270)
307,900 shares@ US$1.95780.6% of flowCommon StockSEC:0000919574-24-004878:0
Ideal exit: 19 May 2025 (T+270)
250,000 shares@ US$1.85290.4% of flowCommon StockSEC:0000919574-24-004812:0
Ideal exit: 16 May 2025 (T+270)
1,200,000 shares@ US$1.59461.8% of flowCommon StockSEC:0000919574-24-004802:0
Ideal exit: 11 May 2025 (T+270)
525,408 shares@ US$1.61490.8% of flowCommon StockSEC:0000919574-24-004593:0
Ideal exit: 6 May 2025 (T+270)
500,000 shares@ US$1.57240.7% of flowCommon StockSEC:0000919574-24-004339:0
Ideal exit: 4 May 2025 (T+270)
200,000 shares@ US$1.58390.3% of flowCommon StockSEC:0000919574-24-004280:1
Ideal exit: 2 May 2025 (T+270)
1,000,000 shares@ US$1.63191.6% of flowCommon StockSEC:0000919574-24-004280:0
Ideal exit: 29 Apr 2025 (T+270)
655,000 shares@ US$2.051.3% of flowCommon StockSEC:0000919574-24-003795:0
100,000 shares@ US$2.600.2% of flowCommon StockSEC:0000919574-24-003356:0
Ideal exit: 17 Feb 2025 (T+270)
100,000 shares@ US$2.58130.2% of flowCommon StockSEC:0000919574-24-003308:0
Ideal exit: 14 Feb 2025 (T+270)
500,000 shares@ US$2.56511.2% of flowCommon StockSEC:0000919574-24-003252:0
Ideal exit: 9 Feb 2025 (T+270)
150,000 shares@ US$17.546.4% of flowCommon Stock, par value $.001 per shareSEC:0000919574-24-002732:0
32,525,821 shares@ US$2.7584.3% of flowCommon StockSEC:0000919574-24-002115:0
250,000 shares@ US$2.570.6% of flowCommon StockSEC:0000919574-24-001888:0
Ideal exit: 29 Nov 2024 (T+270)
11,246,525 sharesCommon StockSEC:0000919574-24-000224:0
927,165 shares@ US$11.1925.5% of flowCommon Stock, par value $.001 per shareSEC:0000919574-23-005783:0
Ideal exit: 15 Jul 2024 (T+270)
58,465 shares@ US$13.20011.8% of flowCommon Stock, par value $.001 per shareSEC:0000919574-23-004543:0
Ideal exit: 5 May 2024 (T+270)
50,000 shares@ US$22.54862.7% of flowCommon Stock, par value $.001 per shareSEC:0000919574-23-003449:0
Ideal exit: 13 Feb 2024 (T+270)
131,428 sharesCommon Stock, par value $.001 per shareSEC:0000919574-23-003420:0
25 of 41 declarations
About Casdin Partners Master Fund, L.P.
Casdin Partners Master Fund, L.P. is a director and insider for several companies, including Verve Therapeutics, Inc. and Absci Corp.
